<DOC>
	<DOCNO>NCT00784134</DOCNO>
	<brief_summary>The overall objective Phase III clinical trial obtain information population 500 ICH subject intraventricular hemorrhage ( IVH ) , representative current clinical practice national demographic ICH regard benefit ( lack thereof ) IVH clot removal subject function measure modified Rankin Scale ( mRS ) . This application request fund five year initiate Phase III randomize clinical trial ( RCT ) test benefit clot removal intraventricular hemorrhage . The investigator propose compare extraventricular drainage ( EVD ) use plus recombinant tissue plasminogen activator ( rt-PA ; Alteplase ; Genentech , Inc. , San Francisco , CA ) EVD+ placebo management treatment subject small intracerebral hemorrhage ( ICH ) large intraventricular hemorrhage ( IVH define ICH &lt; 30 cc obstruction 3rd 4th ventricle intraventricular blood clot ) .</brief_summary>
	<brief_title>Clot Lysis : Evaluating Accelerated Resolution Intraventricular Hemorrhage Phase III</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Cerebral Hemorrhage</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>Age 1880 Symptom onset less 24 hr prior diagnostic CT scan Spontaneous ICH less equal 30 cc primary IVH IVH obstruct 3rd and/or 4th ventricle ICH clot stability 6 hour post IVC placement IVH clot stability 6 hour post IVC placement Catheter tract bleed stability 6 hour post IVC placement EVD place per standard medical care SBP le 200 mmHg sustain 6 hour prior drug administration Able randomize within 72 hour diagnostic CT scan Historical Rankin 0 1 Suspected untreated ruptured cerebral aneurysm , AVM , tumor Presence choroid plexus vascular malformation Moyamoya Clotting disorder Platelet count less 100,000 , INR great 1.4 Pregnancy Infratentorial hemorrhage SAH clinical presentation ICH/IVH enlargement stabilize treatment time window Ongoing internal bleeding Superficial surface bleed Prior enrollment study Any condition investigator believe would pose significant hazard subject investigational therapy initiate Planned simultaneous participation ( screen Day30 ) another interventional medical investigation clinical trial . No subject legal representative give write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>intraventricular hemorrhage thrombolysis</keyword>
</DOC>